0001567619-22-014722.txt : 20220801 0001567619-22-014722.hdr.sgml : 20220801 20220801174000 ACCESSION NUMBER: 0001567619-22-014722 CONFORMED SUBMISSION TYPE: 3/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210203 FILED AS OF DATE: 20220801 DATE AS OF CHANGE: 20220801 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Peyer James CENTRAL INDEX KEY: 0001843594 FILING VALUES: FORM TYPE: 3/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39980 FILM NUMBER: 221126042 MAIL ADDRESS: STREET 1: C/O SENSEI BIOTHERAPEUTICS, INC. STREET 2: 1405 RESEARCH BLVD., STE. 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sensei Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001829802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 620 PROFESSIONAL DRIVE CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: (240) 243-8000 MAIL ADDRESS: STREET 1: 620 PROFESSIONAL DRIVE CITY: GAITHERSBURG STATE: MD ZIP: 20879 3/A 1 doc1.xml FORM 3/A X0206 3/A 2021-02-03 2021-02-03 0 0001829802 Sensei Biotherapeutics, Inc. SNSE 0001843594 Peyer James C/O SENSEI BIOTHERAPEUTICS, INC. 1405 RESEARCH BLVD. SUITE 125 ROCKVILLE MD 20850 1 0 1 0 Common Stock 2282827 I See footnote Series AA Preferred Convertible Stock Common Stock 110729827 I See footnote Series BB Preferred Convertible Stock Common Stock 4821996 I See footnote Stock Option (right to buy) 3.22 2030-08-04 Common Stock 19520 I See footnote These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Dr. Peyer disclaims beneficial ownership of such shares. Each share of the Series AA Preferred Stock and Series BB Preferred Stock is convertible, at any time, at the holder's election, into 0.0208333 shares of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series AA Preferred Stock and Series BB Preferred Stock will automatically convert into 0.0208333 shares of the Issuer's common stock. The Series AA Preferred Stock and Series BB Preferred Stock haves no expiration date. Dr. Peyer disclaims beneficial ownership of such shares. The shares subject to the option vest monthly over twenty-four (24) months from the vesting commencement date, March 31, 2020, subject to the continuous service of James Peyer on the Issuer's Board of Directors. Dr. Peyer is the Chief Executive Officer of Cambrian and disclaims beneficial ownership of such shares. Amendment filed solely to correct the number of shares owned. /s/ Sarah Field, Attorney-in-Fact 2022-08-01